TY - JOUR T1 - Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL) JF - Anticancer Research JO - Anticancer Res SP - 4471 LP - 4479 DO - 10.21873/anticanres.14452 VL - 40 IS - 8 AU - RIRI YOKOTA AU - SHUN HASHIMOTO AU - IKUKO WATANABE AU - SATOSHI KISHIMOTO AU - MASAAKI TOYAMA AU - MIKA OKAMOTO AU - MAKOTO YOSHIMITSU AU - KENJI ISHITSUKA AU - YUJI ITO AU - MASANORI BABA Y1 - 2020/08/01 UR - http://ar.iiarjournals.org/content/40/8/4471.abstract N2 - Background/Aim: Adult T-cell leukemia (ATL) is a hematological malignancy caused by infection with human T-cell leukemia virus type 1 (HTLV-1). Chemotherapy, antibody therapy, and bone marrow transplantation are used to treat this disease, however, median survival time has not been significantly improved. Our aim was to develop and evaluate a novel antibody-drug conjugate (ADC) with regards to cell cytotoxicity and target specificity. Materials and Methods: In this study, we have constructed a novel ADC, which is composed of an anti-CD70 single chain Fv-Fc antibody conjugated with the anticancer agent emtansine using a novel antibody modification method. Cell cytotoxicity and target specificity were assessed using a cell proliferation assay. Results: The anti-CD70 ADC selectively killed HTLV-1-infected cells and ATL cells without affecting other cells. Conclusion: The anti-CD70 ADC offers some chemotherapeutic potential for the treatment of ATL. ER -